{"name":"Liminal BioSciences Ltd.","slug":"liminal-biosciences-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Fezagepras","genericName":"Fezagepras","slug":"fezagepras","indication":"Other","status":"discontinued"},{"name":"PBI-4050 and midazolam","genericName":"PBI-4050 and midazolam","slug":"pbi-4050-and-midazolam","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Fezagepras","genericName":"Fezagepras","slug":"fezagepras","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PBI-4050 and midazolam","genericName":"PBI-4050 and midazolam","slug":"pbi-4050-and-midazolam","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOS0VvM0tYUlZILVloSC13MjBwMEppN0UzV1JSSk1MOGdYVGVQbjgxMFZXU2xISmNJbVRxeHhYNG5lMlV6eDRtUGR5Ulg4WnFSRElLeXVxQ2Y4eHp2MENrV3BLdWJJMXBuU2FFVXo4TzJKSGI4RFotU2JibmtLM1VKdEd6QVdoT1g4Nm1TTGk3d3lCMmNISXA2NUM2OE9EX1hSSVo3WThVZG1pdjcyMF90NEdfWXJWSE5GV1U0STRrUlhlbnJKRjc3UDdQWlpxRl95MFJITEc2a0VwOThiSWZzTTFB?oc=5","date":"2023-09-26","type":"pipeline","source":"PR Newswire","summary":"LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP - PR Newswire","headline":"LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNbV96b1NyZTRWY242VVBEN2gwNHdsdWRBUWk1aWJpOFRVWWEycVJtbGxxSVN3dkZycnNMT1gwTjBUa2YwaVNOTlVIREJ5d1RNc0FUamVwNC1Oa0h0VU9uUlNTODBOSEhUWTlWWXA1TVpBMU5oWm0yUmp5YTM1RjRxWEhNRndPak45dVhVeU14Rm1fUDRXeFFiVmQ1bjRwcVZVc2o0dmpEUWtrcmp6QVZVOG5OVno2RnVqRGN4VzRneXJTbFJsTlloTnI2Y3hldTVUSjlHU0xoN3RIeTBpd0tJMjRB?oc=5","date":"2023-09-19","type":"pipeline","source":"Newswire Canada","summary":"LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP - Newswire Canada","headline":"LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOMFRfTUd3MXctc2lLSnZ1SjhpLWJVVVBfbWhMQ3QtakcwVzFVQWpjN2VJS0FlY3FaMlZtUHJXSjdncEJ4dVY0WGVJTUpjMllFOXJEQThqeTZjRFVNXzMxbmlXRHV0UUdhcGZnVHJWMlhLbHRJTkR5alA3aER1bTdxTXhaS2pyOU84T0VvdXVrQ3IzZThTYWszZHkwdzJ2SFJBemc?oc=5","date":"2023-06-06","type":"pipeline","source":"BioWorld News","summary":"Liminal Biosciences announces preclinical pipeline progress - BioWorld News","headline":"Liminal Biosciences announces preclinical pipeline progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPNGlzVXF2NW1QYUVBZ1pveXlic3pjLTFNdDFnQUlIaHF1Y2hsUjJjQkVHcUhpbi1xVGhLZmNJeEZoeVNudnQzemlid1lvZUg2Sm42eDBOZWp4ZGJlMTUyR3ltR096TDU1djNibV96WWFxaHNRMFR5TlhsOFg4b3B4bm1FWlBvdmQ5b050N05ZdmpOSU45c3d3T1owRFZMX0N0OHBhLVpwWXU4VDc3anlZbnNOR19VbU1LR1ZSNTEwZ3hUUzB2dGc?oc=5","date":"2022-07-21","type":"pipeline","source":"PR Newswire","summary":"Liminal BioSciences Announces Discontinuation of Fezagepras Development - PR Newswire","headline":"Liminal BioSciences Announces Discontinuation of Fezagepras Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNWW5hTTJSa1pVNWI2MFJPS1pnN1VPbXVYVy14ZVU5V0I0OFFUTFR0eXVqQktVMkhZU2ZzMXYtZ3Y5RW1NR09hRWJLVUlEV21XUW5ub0Y0dDBKV1ZERVg0MVZKamo1UmxvZjNYTDZUTnlmX1MzeDJVSmltU1dIOXJiQ2RsU1ptV1N6QVRZZExldmU3YnI3UXhfZmtfVDktZTZQRlZncEd3WjM2Tm5xTWJyMlA5UnR0cnlLXzlXdjV3ZWctNkxEZ0hXc0loSVQ3dw?oc=5","date":"2022-01-19","type":"pipeline","source":"Business Wire","summary":"Expansion Therapeutics Appoints Gary Bridger, Ph.D., to Its Board of Directors - Business Wire","headline":"Expansion Therapeutics Appoints Gary Bridger, Ph.D., to Its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBLNTdKT3NKaEZjbzFhSzNtOEJDUTVaVDlnREFNU1RqWmtPN3JvY3dURXJBZHRyNmtveW5GQzhuaDFRWFZ1TDc2ZFFyMXk2US1s?oc=5","date":"2021-09-15","type":"pipeline","source":"The Motley Fool","summary":"Idera Pharmaceuticals - IDRA - Stock Price & News - The Motley Fool","headline":"Idera Pharmaceuticals - IDRA - Stock Price & News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNMkJDbUVsLXRpZXpXUUt4VUZOYk9fb1ZJcS1SdjdnOUxhbmxJbTctSWp5aHB1eUFPVklXNm9uRWhZdE5RQkRCR1NxUUh4S3l6ejFnU1E0bzhUTEdMZVRzcjV1WXQ0V3E3SzVaby16akt0akRBTUxrMW94YWpYY0RkdU1lUHl2Qm5yMUtuYUxIX0hoOW9hV2hvS0d3UQ?oc=5","date":"2020-04-01","type":"pipeline","source":"Bloomberg Law News","summary":"A Look At What Some of Big Pharma’s Top Lawyers Earned in 2019 - Bloomberg Law News","headline":"A Look At What Some of Big Pharma’s Top Lawyers Earned in 2019","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1FQXpkY241dlJYQk9QcVNjSE5iZm9xN0FMTGlpalNYQnQ3T3M0RHB0Y0x5eHJCakV6ejdZSTdNbUdXdFp2WVJlZWtDY3BfYmRKMEFDZFZZVUszeFg4?oc=5","date":"2019-11-23","type":"pipeline","source":"TradingView","summary":"LMNL Stock Price and Chart — NASDAQ:LMNL - TradingView","headline":"LMNL Stock Price and Chart — NASDAQ:LMNL","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"discontinued":1,"phase_1":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}